A consistent inappropriateness of biomarkers use in clinical practice is still widely observed after several decades from their discovery and limited economic resources require strategies to translate the knowledge on their clinical utility and limitations to users. On the other hand, scientific information on biomarkers is increasingly available. In this contribution, evidence-based instruments to improve appropriateness are described with a deep explanation of evidence-based guideline characteristics and guideline critical appraisal with the AGREE instrument. We present the process developed to produce synthesis of recommendations for clinical use of biomarkers for all clinical spectra (screening, diagnosis, prognosis, and management), with the purpose of representing systematic and critically appraised comparison of guidelines addressing similar topic areas and facilitate the use of guidelines by end-users in a independent and critical way. The project has involved 60 professional figures with expertise in different health and economic fields. A systematic revision of the literature concerning guidelines has been conducted by two independent reviewers of the working group, searching in different databases and scientific web sites. Recommendations regarding biomarkers have been synthesised into synoptical tables. The critical appraisal of each selected guideline has been conducted using the AGREE instrument by at least three independent clinicians of the multidisciplinary expert group. The description of synoptical and AGREE table characteristics and the list of documents analysed is provided.
|Translated title of the contribution||Guidelines for clinical use of biomarkers in oncology: Methodology and reading key|
|Number of pages||9|
|Publication status||Published - Aug 2011|
ASJC Scopus subject areas
- Clinical Biochemistry
- Biochemistry, medical
- Medical Laboratory Technology